These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 22324948

  • 1. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.
    Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ.
    Int J Rheum Dis; 2012 Feb; 15(1):62-8. PubMed ID: 22324948
    [Abstract] [Full Text] [Related]

  • 2. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus.
    Carneiro JR, Sato EI.
    J Rheumatol; 1999 Jun; 26(6):1275-9. PubMed ID: 10381042
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis.
    Rahman P, Humphrey-Murto S, Gladman DD, Urowitz MB.
    J Rheumatol; 1998 Feb; 25(2):243-6. PubMed ID: 9489814
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
    Wenzel J, Brähler S, Bauer R, Bieber T, Tüting T.
    Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
    [Abstract] [Full Text] [Related]

  • 5. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
    Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE.
    Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
    [Abstract] [Full Text] [Related]

  • 6. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus.
    Wilson K, Abeles M.
    J Rheumatol; 1994 Sep; 21(9):1674-7. PubMed ID: 7799348
    [Abstract] [Full Text] [Related]

  • 7. Methotrexate in systemic lupus erythematosus.
    Walz LeBlanc BA, Dagenais P, Urowitz MB, Gladman DD.
    J Rheumatol; 1994 May; 21(5):836-8. PubMed ID: 8064722
    [Abstract] [Full Text] [Related]

  • 8. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 9. Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus.
    Ravelli A, Ballardini G, Viola S, Villa I, Ruperto N, Martini A.
    J Rheumatol; 1998 Mar; 25(3):572-5. PubMed ID: 9517783
    [Abstract] [Full Text] [Related]

  • 10. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V.
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [Abstract] [Full Text] [Related]

  • 11. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S, Nishiyama S, Aita T, Yoshinaga Y.
    Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
    [Abstract] [Full Text] [Related]

  • 12. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I.
    Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
    [Abstract] [Full Text] [Related]

  • 13. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
    Luis M, Pacheco-Tena C, Cazarín-Barrientos J, Lino-Pérez L, Goycochea MV, Vazquez-Mellado J, Burgos-Vargas R.
    Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
    [Abstract] [Full Text] [Related]

  • 14. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease--a review of 36 patients.
    Wise CM, Vuyyuru S, Roberts WN.
    J Rheumatol; 1996 Jun; 23(6):1005-10. PubMed ID: 8782131
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
    van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A, ADORE Study Investigators.
    Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [Abstract] [Full Text] [Related]

  • 17. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, Arnold GE, Tsuji WH, Merrill JT, Chung JB.
    Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
    [Abstract] [Full Text] [Related]

  • 18. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N, Kato Y, Sugii S, Inada S.
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [Abstract] [Full Text] [Related]

  • 19. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis.
    Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R.
    Br J Rheumatol; 1998 Oct; 37(10):1060-8. PubMed ID: 9825744
    [Abstract] [Full Text] [Related]

  • 20. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.